Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer

Pharmacotherapy

Volumn 23, Issue 3, 2003, Pages 315-318

  Horne III, McDonald K ^a   Figg, William D ^b   Arlen, Phil ^b   Gulley, James ^b   Parker, Catherine ^b   Lakhani, Nehal ^b   Parnes, Howard ^b   Dahut, William L ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; DOCETAXEL; THALIDOMIDE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM; VEIN THROMBOSIS;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES; TAXOIDS; THALIDOMIDE; VENOUS THROMBOSIS;

EID: 0037370067     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.3.315.32106     Document Type: Article

References (21)

1. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082-5.
2. Bauer KS, Dixon SC, Figg WD. Inhibition by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol 1998;55:1827-34.
3. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-71.
4. Fine HA, Figg WD, Jaeckle K, et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 2000;18:708-15.
5. Little RF, Wyvill KM, Pluda JM, et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol 2000;18:2593-602.
6. Thomas DA, Kantarjian HM. Current role of thalidomide in cancer treatment. Curr Opin Oncol 2000;12:564-73.
7. Osman K, Comenzo R, Rajkuman SV. Deep venous thrombosis and thalidomide for multiple myeloma. N Engl J Med 2001;344:1951-2.
8. Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001;98:1614-15.
9. Camba L, Peccatori J, Pescarollo A, Tressoldi M, Corradini P, Bregni M. Thalidomide and thrombosis in patients with multiple myeloma. Haematologica 2001;86:1108-9.
10. Zangari M, Siegel E, Barlogie B, et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 2002;100:1168-71.
11. Cavo M, Zamagni E, Cellini C, et al. Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. Blood 2002;100:2272-3.
12. Escudier B, Lassau N, Couanet D, et al. Phase II trial of thalidomide in renal-cell carcinoma. Ann Oncol 2002;13:1029-35.
13. Flageul B, Wallach D, Cavelier-Balloy B, Bachelez H, Carsuzaa F, Dubertret L. Thalidomide et thromboses. Ann Determatol Venereol 2000;127:171-4.
14. Figg WD, Arlen P, Gulley J, et al. A randomized phase II trial of docetaxel (Taxotere) plus thalidomide in androgen-independent prostate cancer. Semin Oncol 2001;28(suppl 15):62-6.
15. Figg WD, Dahut W, Duray P, et al. A randomized phase II trial of thalidomide, an angiogenesis inhibitor in patients with androgen-independent prostate cancer. Clin Cancer Res 2001;7:1888-93.
16. The Leuprolide Study Group. Leuprolide versus diethyl-stilbestrol for metastatic prostate cancer. N Engl J Med 1984;311:1281-6.
17. Drewinko B, Cobb P, Guinee V, Giacco G, Trujillo JM, von Eschenbach A. Untreated prostatic carcinoma is not associated with frequent thrombohemorrhagic disorders. Urology 1987;30:11-17.
18. Prandoni P, Lensing AWA, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125:1-7.
19. Kaushal V, Kohli M, Zangari M, Fink L, Mehta P. Endothelial dysfunction in antiangiogenesis-associated thrombosis [letter]. J Clin Oncol 2002;20:3042-3.
20. Sweeney CJ, Miller KD, Sissons SE, et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor of 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001;61:3369-72.
21. Feenstra J, Vermeer RJI, Stricket BHC. Mesenteric venous thrombosis attributed to docetaxel. Am J Clin Oncol 2000;23:353-4.